USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/26894
Title: Current level of knowledge about Parkinson’s disease cognitive impairment
Authors: Rotaru, Lilia
Grosu, Oxana
Groppa, Stanislav
Keywords: Parkinson’s disease;mild cognitive impairment;dementia
Issue Date: 2023
Publisher: The Scientific Medical Association of the Republic of Moldova
Citation: ROTARU, Lilia, GROSU, Oxana, GROPPA, Stanislav. Current level of knowledge about Parkinson’s disease cognitive impairment. In: The Moldovan Medical Journal. 2023, nr. 2(66), pp. 101-110. ISSN 2537-6373. DOI: https://doi.org/10.52418/moldovan-med-j.66-2.23.15
Abstract: Background: Parkinson’s disease (PD) affects more than 1% of the population aged over 65 years and manifests with both motor symptoms – bradykinesia, rest tremor, rigidity, and non-motor symptoms. Cognitive impairment and dementia are recognized non-motor symptoms that can significantly affect the quality of life of both the patient and caregivers and are a risk factor for institutionalization in nursing homes and a risk factor for early mortality. Cognitive impairment is frequent in Parkinson’s disease (PD) that can develop even before the diagnosis of Parkinson’s disease based on its motor features. Conclusions: There are several clinical, molecular, and imaging factors that constitute risk factors for the development of Parkinson’s disease dementia, in which basal cholinergic and prefrontal dopaminergic systems are involved. Histological changes are Lewy-body, Alzheimer, but also vascular pathology. Clinically can be distinguished subjective cognitive decline, mild cognitive impairment and, subsequently, Parkinson’s disease dementia. There are no remedies with a proven effect to prevent the occurrence of cognitive decline in PD. The only approved drug for already developed D-PD is the cholinesterase inhibitor – donepezil. Non-pharmacological interventions are thought to be beneficial. A multidisciplinary approach to cognitive impairment is recommended, with specific pharmaceutical treatment of the cognitive disorder and comorbidities, and appropriate rehabilitation.
metadata.dc.relation.ispartof: The Moldovan Medical Journal
URI: https://moldmedjournal.md/wp-content/uploads/2024/01/Moldovan-Med-J-2023-Vol66-No2_2.pdf
https://doi.org/10.52418/moldovan-med-j.66-2.23.15
http://repository.usmf.md/handle/20.500.12710/26894
ISSN: 2537-6373
2537-6381
Appears in Collections:Moldovan Medical Journal, December 2023, Vol. 66, No 2

Files in This Item:
File Description SizeFormat 
Current_level_of_knowledge_about_Parkinson_s_disease_cognitive_impairment.pdf270.54 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback